Abstract Total laparoscopic approach for the management of carcinoma of the esophagus has not gained much popularity due to its complexity. The aim of this study was to evaluate safety, feasibility, and outcome of laparoscopic-assisted transhiatal esophagectomy (LATE) for patients with carcinoma of the esophagus. This retrospective study involves a total of 26 patients with carcinoma of the esophagus who were considered for LATE by a single surgical team from January 2010 to September 2014. The median (range) age was 55 years (35-72), and male to female ratio was 20:6. The median (range) operative time, blood loss, and hospital stay were 300 min (180-660), 300 ml (100-500), and 11.5 days (8-25), respectively. Pulmonary complications and cervical anastomotic leak (including one patient with conduit necrosis) occurred in eight (30.7 %) and three (11.5 %) patients, respectively. AJCC stage (7th ed.) was IIA in 12 (46.15 %), IIB in 10 (38.46 %), IIIA in 3 (11.53 %), and IIIB in 1 (3.84 %) patient. Surgical resection margin was negative in all but one patient (3.8 %). The median (range) number of lymph nodes (LN) retrieved was 13 (8-28). During a median follow-up 19 months (8-39), five patients (19.23 %) developed recurrence and three (11.5 %) of them died. LATE is a safe and feasible for the management of selected patients with carcinoma of the lower thoracic esophagus.
Introduction
Transhiatal esophagectomy (THE) is the most widely performed surgery for carcinoma of the esophagus [1, 2] . It has been found to be technically easier, oncologically adequate, and with less mediastinal complications as compared to transthoracic esophagectomy (TTE) [2] . However, it is associated with a risk of iatrogenic injury during blind transhiatal dissection and non-systematic lymphadenectomy. Laparoscopicassisted transhiatal esophagectomy (LATE) is a hybrid technique which is believed to have better visualization of the infracarinal esophagus, improved lymphadenectomy, and lowers the risk of iatrogenic injury. Despite a sound technique, LATE is scarcely reported in literature. Hence, we reviewed our initial experience with LATE in patients with carcinoma of the esophagus.
Methods
The total 26 patients with carcinoma involving the lower thoracic esophagus (infracarinal) and/or gastroesophageal junction were considered for LATE from January 2010 to September 2014. All operations were performed by a single surgical team working at a tertiary care centre in the north India. Written informed consent was obtained from all the patients. As per prevailing guidelines, permission from the ethics committee was not necessary. All patients had confirmed diagnosis of carcinoma (endoscopic biopsy) at the time of surgery. Contrast-enhanced computed tomography (CECT) of the neck, chest, and abdomen was used for preoperative staging and surgical planning. Routine preoperative work up included blood investigation, chest X-ray, electrocardiogram and pulmonary function test. Patients with metastatic or locally advanced disease were excluded from the study. Seventh edition of AJCC staging system was used for the disease stratification.
Operative Procedure
Patients were operated in French position. Hassan's technique was used to create pneumoperitoneum, and total four ports were utilized to complete laparoscopic part. Laparoscopic camera set (Karl Storz), ligaclips (Ethicon), hem-o-lock clips, and ultrasonic shear (Harmonic Gen 4, Johnson & Johnson) were utilized for dissection and division of the vessels. The mobilization of the stomach was completed after the assessment of resectability. The right gastroepiploic artery was preserved, and the left gastric artery was divided between the clips [ Fig. 1c] . The esophagus was mobilized through widened hiatus under direct vision. Mediastinal dissection was carried out carefully to ensure adequate lymphadenectomy as well as preservation of all the vital structures [ Fig. 1D ]. After the completion of laparoscopic part of dissection, a cervical incision was made along the lower part of the left sternocleidomastoid muscle which extended across the midline. The deep fascia and muscles were dissected to expose the esophagus. The esophagus was encircled with great care to avoid injury to the left recurrent laryngeal nerve. A small (5-6 cm) upper midline incision was made to complete transhiatal mobilization as described by Orringer et al. [1] . The esophagus was divided about 4-5 cm distal to cricoesophageal junction, and specimen was delivered through abdominal wound. Endo GIA stapler (75 mm, green cartridge, Ethicon) was utilized for the creation of gastric conduit and excision specimen [ Fig. 1D ]. Gastric conduit was brought to the neck through orthotopic route, and cervical-esophagogastric anastomosis (CEGA) was completed with interrupted 3-0 silk sutures (Ethicon). A feeding jejunostomy was fashioned by Stamm's method. An abdomen wound was closed after placement of drains in the right pleural space and left sub-hepatic space. A cervical wound was closed after placement of a 18 FG suction drain (Romsons) near CEGA. 
Results
Median age was 55 years and most patients were male (77 %). Majority of the patients were from semi-urban areas and had poor socioeconomic status. Seventeen patients (65 %) were chronic smokers, and 3-15 % patients had associated comorbid illnesses. Progressive dysphagia and weight loss were the most common symptoms (Table 1) . Median operative time was 311(180-660) min, median blood loss was 300 ml (100-500), and five patients (19.23 %) required blood transfusion. Mean postoperative hospital stay was 12 (8-17) days, and mean ICU stay was 3 (2-4) days. Three (11.53 %) patients had anastomotic leak and one (3.8 %) of them required reexploration and replacement gastric conduit by colonic conduit (Table 2) . Twenty-three (88 %) patients had adenocarcinoma, and three (12 %) patients had squamous cell carcinoma. AJCC stage was II in 22 patients (85 %) and III in four (15 %) patients. Minimum number of lymph nodes were six; maximum number was 23; and 14 patients had LN positive disease. Resection margins were negative in all but one patient (Table 3) . Thirty-day mortality was 0. Patients with stage 3 disease received cisplatin-based adjuvant chemotherapy. With a median follow-up of 19 months, three patients expired. Among them, one patient who had margin positive disease received adjuvant chemotherapy and survived for 13 months after surgery.
Discussion
This study describing a novel modification in esophagectomy has shown that LATE can be performed safely with no postoperative mortality, minimum hospital stay including short ICU stay, comparable in postoperative morbidity, and oncological adequacy.
While thoracoscopic approach is fastly replacing open thoracoscopic approach in mid-thoracic esophageal tumors, the application of minimally invasive techniques to transhiatal approach in lower thoracic esophageal tumors has been slow. DePaula et al. [3] first reported the technique of laparoscopic approach to THE in 1995. In 2005, Avital et al. [4] presented a series on LATE with 22 patients, 19 among which had esophageal cancer. We accomplished zero 30-day mortality in 26 patients who underwent LATE. Since LATE is ideal for lower thoracic esophageal tumors, majority (88.46 %) were adenocarcinoma. It was around 60 % in Orringer [1] series, 96 % in Hulschers [5] series, and 76 % were adenocarcinoma in Luketich's [6] largest MIE series.
Mean intraoperative blood loss is 300 ml in our series and is less when compared to open THE series (368 ml) and it was 220 ml in Avital et al. [4] series. This can be attributed to mediastinal dissection done under vision in LATE. Mean duration of surgery is 311 min and is in tune with literature range. In all the 26 cases, we could successfully complete the transhiatal dissection laparoscopically.
Mean postoperative hospital stay was 12 days (range 8-25 days) with one patient needing re-explorative surgery for conduit necrosis diagnosed on postoperative day 1 and was managed with colon pull-up. Three patients had neck leak and was managed with conservative measures.
Hulscher et al. [5] conducted the largest RCT comparing THE and TTE. Eventhough the open TTE showed a trend towards better survival and nodal clearance, there was an increased respiratory complications, wound infections, and early postoperative mortality associated with this procedure as compared to THE [7, 8] . Orringers [1] series including 2000 THE has shown that several refinements in the procedure have reduced the historic mortality and morbidity associated with THE. In a recent revision, they have shown mortality rate of 1 %, minimal postoperative morbidity, and better survival. In parallel with these results, ( Table 4 ) present series that has shown better oncological clearance, less postoperative morbidity, and minimal hospital stay. In terms of technicality, our results are comparable with largest MIE series by Luketich et al. [6] , reflecting the positive side of the application of minimally invasive technique to one of the wellestablished open approach.
The extent of nodal clearance plays an important role in staging and oncological outcome [9, 10] . TTE holds an upper hand in this regard with better exposure and detailed mediastinal nodal dissection. In our current series, the average number of lymph nodes cleared was 13(8-28) with mean positive nodes being 2 (0-6) which was comparable to most of the minimal invasive series.
Most of the minimally invasive procedures have a steep learning curve while LATE is relatively easy to perform. Literature on LATE is scarce, and this is the largest series till date reported in English medical literature to the best of our knowledge. A small sample size and a lack of comparable arm are the limitations of our study.
Conclusions
LATE is a safe and feasible alternative to THE in the selected group of lower thoracic esophageal cancers. However, longterm follow-up results are awaited.
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